To the Editor: Janus kinase inhibitors have shown promise in the treatment of vitiligo. [1] [2] [3] In our original trial of topical ruxolitinib cream, the response was predominantly seen in facial vitiligo. 3 We carried out a 32-week extension with an objective to determine if continued use of topical ruxolitinib would cause repigmentation in locations that previously did not respond. The primary end-point was an improvement in Vitiligo Area Scoring Index (VASI) at 52 weeks.
The study was approved by the Tufts institutional review board and was conducted with the same methodology as the original trial. 3 Patients continued to be treated with twice-daily application of topical ruxolitinib 1.5% cream on areas predetermined at baseline. Application of the cream was limited to 10% of the body surface area or 3.75 g/application. On the basis of previous evidence for synergism of Janus kinase inhibitors and ultraviolet light, 4, 5 concomitant narrow band ultraviolet B (NB-UVB) treatment was permitted.
Eight of 9 patients continued in the extension study. Five patients completed the trial, while 3 dropped out due to lack of response. Three patients opted for optional NB-UVB (Supplemental Table I ; available at http://www.jaad.org). A statistically significant mean improvement in overall VASI of 37.6% 6 31.2% (P ¼ .011) was observed for enrolled patients (n ¼ 8) at week 52 from baseline (Fig 1) .
Five of 8 patients had a treatment response. In patients with [0.5% facial surface area affected (n ¼ 4), a statistically significant mean improvement of 92% 6 7.1%, (P ¼ .0001) in facial VASI was seen at week 52, with 1 patient being completely repigmented. Three of 6 patients had a response on their nonacral upper extremities, with a VASI improvement of 12.6% 6 19.5%; 2 of these 3 had been treated with combination phototherapy. Slight acral repigmentation was seen in a patient at week 38. Two of 3 patients (both of whom had opted for combination phototherapy) responded on the trunk with a mean VASI improvement of 16.7% 6 16.7%. These 2 patients had failed prior phototherapy and topical ruxolitinib monotherapy on truncal lesions (Fig 2) . Mean percent improvement of VASI score for total, facial, acral, truncal, and nonacral extremities from baseline to week 52 for all enrolled patients with vitiligo (n ¼ 8). Data from their last recorded visit were used for patients (n ¼ 3) who dropped out of the study. Phototherapy was permitted after week 20 (bold black arrow). VASI, Vitiligo Area Scoring Index.
Two patients developed new lesions on areas not being treated, while none of the treated areas got worse. A mean improvement of 16.7% 6 35.6% was seen in Physician Global Vitiligo Assessment, a mean improvement of 1.5 was seen in Dermatology Life Quality Index, and the change in body surface area was 20.78% 6 35.35% at week 52; however, none of these data were statistically significant.
Five patients who completed the trial were followed up at 6 months after treatment discontinuation, and all of them maintained response, with maximum duration of [40 weeks. Interestingly, relapse has been seen in a patient after the use of oral ruxolitinib. 2 Minor adverse events, including erythema in 3 of 8 patients and transient acne in 2 patients, were observed. Limitations include open-label design, a small sample size, and inability to monitor natural sun exposure. A limited response was seen after an additional 32 weeks, but improvement was seen with NB-UVB and topical ruxolitinib combination. In conclusion, patients with vitiligo who used topical ruxolitinib 1.5% cream twice daily with optional NB-UVB saw a statistically significant mean improvement in overall VASI score at week 52, and this effect was most pronounced for those treating facial vitiligo. Conflicts of interest: Dr Rosmarin has served on advisory boards or is a consultant to Pfizer, Eli To the Editor: Alopecia areata (AA) is an autoimmune condition with limited treatment options, particularly in pediatric populations. There are no Food and Drug Administrationeapproved treatments for children with AA, and medications used for alopecia totalis (AT) and alopecia universalis (AU) lack large, controlled studies. 1 The mainstays of treatment are topical or intralesional steroids and irritant therapy. Some families opt for systemic therapies, including oral corticosteroids or off-label use of immunosuppressive drugs, such as methotrexate, cyclosporine A, mycophenolate mofetil, or azathioprine.
Clinical trials have shown benefit from oral Janus kinase (JAK) inhibitors in adults with AA. 2 Potential adverse effects, such as increased risk for infection and myelosuppression, make oral formulations less appealing for pediatric patients. It is presumed that topical JAK inhibitors have minimal adverse effects, the main one being irritation in the area of application. Considering these small molecules are poorly soluble in water, JAK inhibitors might be most effective when delivered in a liposomal base, which often consist of phospholipids mixed with water. 3 Clinical trials investigating the efficacy of topical formulations for adults are underway, but data regarding pediatric patients are limited to case reports. [3] [4] [5] We report the characteristics and outcomes of 11 pediatric patients ages 4-16 years with AA, AT, or AU, treated with nonpatented formulations of 2% topical tofacitinib prepared by Chemistry Rx (Philadelphia, PA) (Table I) .
Patients had previously failed 15-day or 3-week courses of oral prednisone or prednisolone (1 mg/kg daily for 5-7 days, then 0.5 mg/kg daily for 5-7 days, then 0.25 mg/kg daily for 5-7 days) as well as class 1 or 2 topical steroids (Table I ). Patients 1, 3, 7, and 9 had failed at least 3 months of oral methotrexate (0.5 mg/kg). Seven patients had a family history positive for autoimmune disease. Alopecia had been present for at least 2 years in all individuals. Of 11 patients, 2 were boys and 9 girls. Mean duration of treatment was 34.5 weeks.
The average change in Severity of Alopecia Tool (SALT) score was a reduction of 32.3%. Eight of 11 patients demonstrated an improvement in SALT score ( Supplemental Fig 1, A-C ; available at http://www.jaad.org). Three had cosmetically acceptable regrowth. 6 Hair growth was considered cosmetically acceptable if it was sufficient to cover the scalp or able to conceal residual areas of hair loss. 6 All patients tolerated treatment without adverse effects, which were recorded at each visit on the basis of a standard review of systems screening for new fatigue, infection, headache, rash, and gastrointestinal symptoms. One individual reported application-site irritation. Blood levels of tofacitinib were not obtained.
Although patients 1 and 8 responded initially, they experienced loss of regrowth 9-12 months after starting therapy. Patient 2 did not improve with topical tofacitinib but responded to a subsequent course of the oral formulation. Six patients continue to apply a 2% liposomal formulation. One patient stopped all alopecia treatment.
These limited results suggest that topical tofacitinib might be a reasonable adjunct or second-line therapy for pediatric patients with AA, AT, and AU for whom systemic therapies are not desired. Controlled studies with larger cohorts are needed to determine efficacy and identify factors associated with favorable outcomes.
